Literature DB >> 20443018

Clinical progression in Charcot-Marie-Tooth disease type 1A duplication: clinico-electrophysiological and MRI longitudinal study of a family.

José Berciano1, Elena Gallardo, Antonio García, César Ramón, Jon Infante, Onofre Combarros.   

Abstract

Long-term follow-up studies in Charcot-Marie-Tooth disease type 1 duplication (CMT1A) are scanty. Here we describe a longitudinal study in a CMT1A pedigree. Our CMT1A pedigree comprised 11 examined patients, ages between 13 and 83 (median, 36) years, serially evaluated for up to 26 years. In all 11 patients we carried out electrophysiological evaluation, and in three of them magnetic resonance imaging (MRI) of lower-limb musculature. The 54-year-old proband patient, yearly examined as of age 28, developed at age 48 gradual and progressive distal lower-leg weakness ascending to thigh musculature. His serial electrophysiological studies showed diffuse slowing of motor conduction velocity, absence or severe attenuation of distal compound muscle action potentials, and spontaneous muscle activity in the tibialis anterior and rectus femoris. Two MRI studies of lower limbs, at ages 51 and 54, showed extensive fatty atrophy of lower-leg musculature, and progressive and distally accentuated fatty atrophy of anterior and posterior femoral muscles. An outstanding finding in the first MRI was the presence of marked edema of anterior femoral musculature, which to a great degree was replaced by fatty atrophy in the second study. Muscle edema was also noted in lower-leg and posterior femoral musculature. There was minimal fatty atrophy of the gluteus maximus, the remaining pelvic muscles being preserved. The other ten patients showed mild or moderate phenotype, which remained quiescent over the period of observation. Electrophysiological studies disclosed diffuse and uniform slowing of nerve conduction velocities; in no case was spontaneous muscle activity recorded. MRI showed the CMT1A characteristic pattern of distally accentuated fatty atrophy involving foot and lower-leg musculature with preservation of thigh musculature. We conclude that a small proportion of patients with CMT1A develop a late progression of disease manifested with accentuated distal leg weakness ascending to involve thigh musculature, and that long-term follow-up is essential for its detection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20443018     DOI: 10.1007/s00415-010-5580-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

Review 1.  MR imaging in nonneoplastic muscle disorders of the lower extremity.

Authors:  Joshua M Farber; Kenneth A Buckwalter
Journal:  Radiol Clin North Am       Date:  2002-09       Impact factor: 2.303

2.  Duplication of part of chromosome 17 is commonly associated with hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease type 1).

Authors:  P J Hallam; A E Harding; J Berciano; D F Barker; S Malcolm
Journal:  Ann Neurol       Date:  1992-05       Impact factor: 10.422

3.  Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies.

Authors:  P J Dyck; E H Lambert
Journal:  Arch Neurol       Date:  1968-06

4.  Early morphological features in dominantly inherited demyelinating motor and sensory neuropathy (HMSN type I).

Authors:  A A Gabreëls-Festen; E M Joosten; F J Gabreëls; F G Jennekens; T W Janssen-van Kempen
Journal:  J Neurol Sci       Date:  1992-02       Impact factor: 3.181

5.  Reliability and validity of the CMT neuropathy score as a measure of disability.

Authors:  M E Shy; J Blake; K Krajewski; D R Fuerst; M Laura; A F Hahn; J Li; R A Lewis; M Reilly
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

6.  Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A.

Authors:  K M Krajewski; R A Lewis; D R Fuerst; C Turansky; S R Hinderer; J Garbern; J Kamholz; M E Shy
Journal:  Brain       Date:  2000-07       Impact factor: 13.501

7.  MCP-1/CCL2 modifies axon properties in a PMP22-overexpressing mouse model for Charcot-Marie-tooth 1A neuropathy.

Authors:  Bianca Kohl; Stefan Fischer; Janos Groh; Carsten Wessig; Rudolf Martini
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

8.  Denervated human skeletal muscle: MR imaging evaluation.

Authors:  J L Fleckenstein; D Watumull; K E Conner; M Ezaki; R G Greenlee; W W Bryan; D P Chason; R W Parkey; R M Peshock; P D Purdy
Journal:  Radiology       Date:  1993-04       Impact factor: 11.105

9.  Neuropathy progression in Charcot-Marie-Tooth disease type 1A.

Authors:  M E Shy; L Chen; E R Swan; R Taube; K M Krajewski; D Herrmann; R A Lewis; M P McDermott
Journal:  Neurology       Date:  2008-01-29       Impact factor: 9.910

10.  The clinical features of hereditary motor and sensory neuropathy types I and II.

Authors:  A E Harding; P K Thomas
Journal:  Brain       Date:  1980-06       Impact factor: 13.501

View more
  4 in total

1.  Evolution of Charcot-Marie-Tooth disease type 1A duplication: a 2-year clinico-electrophysiological and lower-limb muscle MRI longitudinal study.

Authors:  Ana L Pelayo-Negro; Elena Gallardo; Antonio García; Pascual Sánchez-Juan; Jon Infante; José Berciano
Journal:  J Neurol       Date:  2014-01-22       Impact factor: 4.849

Review 2.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

3.  MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study.

Authors:  Jasper M Morrow; Christopher D J Sinclair; Arne Fischmann; Pedro M Machado; Mary M Reilly; Tarek A Yousry; John S Thornton; Michael G Hanna
Journal:  Lancet Neurol       Date:  2015-11-06       Impact factor: 44.182

4.  Cavovarus deformity in Charcot-Marie-Tooth disease: is there a hindfoot equinus deformity that needs treatment?

Authors:  Nicholas A Beckmann; Sebastian I Wolf; Daniel Heitzmann; Annika Wallroth; Sebastian Müller; Thomas Dreher
Journal:  J Foot Ankle Res       Date:  2015-11-26       Impact factor: 2.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.